Articles
| Open Access |
https://doi.org/10.55640/ijmm-03-12-01
ETIOLOGICAL AND PATHOGENETIC FACTORS IN THE DEVELOPMENT OF COGNITIVE DISORDERS IN PARKINSON'S DISEASE
Abstract
Parkinson's disease (PD) is rightly recognized as one of the most common age-related diseases of the brain. Despite the well-known definition of PD as a movement disorder, a large amount of information has recently accumulated with the recognition of this disease as a heterogeneous multisystem disorder in which neurotransmitter systems (serotonergic, noradrenergic and cholinergic) play an important role. These neurotransmitters determine the severity of the non-motor signs of PD. The development of dementia in PD generates a heavy burden not only of an economic but also of a social nature. In this regard, over the past 30 years, scientists in this field of medicine have been conducting more and more research to identify the role and place of biomarkers in predicting the development of dementia in PD, which will also allow the development of preventive methods of correction at the early stages of cognitive impairment. This review article summarised the primary modern information regarding the aetiology and pathogenesis of cognitive disorders in PD.
Keywords
Parkinson's disease, cognitive disorders, dementia
References
The association of incident dementia with mortality in PD. / G. Levy, M.X. Tang, E.D. Louis, et al. // Neurology 2016;59:1708–1713.
Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study. / Y. Winter, S. von Campenhausen, M. Arend, et al. // Parkinsonism Relat. Disord. 2016;17:265–269.
Lang A.E., Obeso J.A. Time to move beyond nigrostriatal dopamine deficiency in Parkinson’s disease. // Ann. Neurol. – 2004;55:761–765.
The influence of age and gender on motor and non-motor features of early Parkinson’s disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. / K. Szewczyk-Krolikowski, P. Tomlinson, K. Nithi, et al. // Parkinsonism Relat. Disord. – 2014;20:99–105.
Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. / E.F. Augustine, A. Perez, R. Dhall, et al. // PLoS One. - 2015;10(7):e0133002.
Sex differences in cognition among Chinese people with Parkinson's disease. / L. Gao, K. Nie, H. Tang, et al. // J. Clin Neurosci. - 2015;22(3):488-92.
Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson’s disease progression in the DATATOP cohort. / T. Stewart, C. Liu, C. Ginghina, et al. // Am. J. Pathol. - 2014;184(4):966-975.
Coughlin D.G., Hurtig H.I., Irwin D.J. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. // Mov. Disord. - 2020;35(1):5-19.
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. / J.L. Robinson, E.B. Lee, S.X. Xie, et al. // Brain. 2018;141(7):2181-2193.
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. / Y. Compta, T. Valente, J. Saura, et al. // J. Neurol. - 2015;262(2):294-306.
Jellinger K.A., Attems J. Cerebral amyloid angiopathy in Lewy body disease. // J. Neural. Transm. (Vienna). - 2008;115(3):473-82.
Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. / D. Hansen, H. Ling, T. Lashley, et al. // Neuropathol Appl Neurobiol. - 2021 Feb;47(1):143-156.
Associated factors for REM sleep behaviour disorder in Parkinson's disease. / F. Sixel-Doring, E. Trautmann, B. Mollenhauer, C. Trenkwalder. // Neurology. - 2014;77:1048–1054.
Rapid eye movement sleep behaviour disorder and risk of dementia in Parkinson’s disease: a prospective study. / R.B. Postuma, J.A. Bertrand, J. Montplaisir, et al. // Mov. Disord. - 2015;27:720–726.
Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behaviour disorder. / L.M. Chahine, S.X. Xie, T. Simuni, et al. // Parkinsonism Relat Disord. - 2016;27:102-6.
Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease. / E. Forbes, T.F. Tropea, S. Mantri, et al. // Mov. Disord. Clin. Pract. - 2021;8(2):254-263.
Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies. / Y. Guo, W. Xu, F.T. Liu, et al. // Mov. Disord. - 2019;34(6):876-883.
Risk score for predicting dementia risk in 20 years among middle-aged people: a longitudinal, population-based study. / M. Kivipelto, T. Ngandu, T. Laatikainen, et al. // Lancet Neurol. - 2016;5(9):735-741.
Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. / L.M. Chahine, C. Dos Santos, M. Fullard, et al. // Eur. J. Neurol. - 2019;26(2):246-e18.
Diabetes mellitus and Parkinson’s disease. / G. Pagano, S. Polychronis, H. Wilson, et al. // Neurology – 2018;90:e1654–e1662.
The detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson’s disease. / S.J. Chung, S. Jeon, H.S. Yoo, et al. // Parkinsonism Relat. Disord. – 2019;64:54–59.